uniQure has filed the first-ever gene therapy application for Huntington's disease. The science is compelling, the regulatory backstory is dramatic, and the stakes for 30,000 Americans and 200,000 at-risk individuals could not be higher.
AstraZeneca's Etcamah became the first FDA-approved cancer therapy triggered by a blood test detecting resistance before imaging shows progression. The approval rewrites how oncologists think about treatment switching in HR-positive breast cancer.
The FDA's approval of Zanvastro marks the first treatment ever approved for Alexander disease, signaling a broader shift in how RNA-targeted therapies can address ultra-rare neurological conditions.
ARPA-H's $125 million GIVE program aims to revolutionize RNA medicine manufacturing through distributed, automated platforms that can produce personalized therapies on demand near patients.
GSK is advancing an mRNA flu vaccine that targets both hemagglutinin and neuraminidase into Phase 3, a more ambitious dual-antigen approach than Moderna's recently approved mFlusiva. Here is what the science means and why it matters.
Novartis and Bristol Myers Squibb paused their autoimmune CAR-T programs on the same day, forcing the field to reckon with safety challenges that may be inherent to translating oncology science into autoimmune disease.
The FDA's approval of BESREMi marks the first new therapy for essential thrombocythemia in nearly 30 years, signaling a shift toward disease-modifying treatments that target the molecular drivers of this rare blood cancer.
Novartis, Amgen, and Eli Lilly are racing to address Lp(a), a genetic cardiovascular risk factor affecting 1 in 5 people with no approved treatment. The first pivotal outcomes data could arrive within weeks.
The FDA's approval of Rasonque marks a watershed moment in oncology—the first therapy to directly target RAS, ending three decades of failed attempts to drug one of cancer's most intractable targets.
Takeda's FDA approval of Orzeyful marks a paradigm shift in narcolepsy treatment—the first medicine to directly target orexin deficiency rather than manage symptoms.
Roche commits $2.3 billion to Hanmi's UCN2 obesity drug candidate, signaling a strategic shift toward muscle-preserving mechanisms beyond GLP-1 agonists.
The FDA approved a subcutaneous starting dose of lecanemab, allowing Alzheimer's patients to begin treatment at home via weekly self-injection—removing a major access barrier to this disease-modifying therapy.
Biotechnology
The FDA's accelerated approval of Ultragenyx's Genglycos marks the first gene therapy for glycogen storage disease type Ia, signaling a new era in treating rare metabolic diseases at their genetic root.
Wall Street Wire
Moderna's cancer vaccine with Keytruda just worked. That's huge: the stock nearly tripled, and the whole biotech index moved. As attention around oncology innovators increases, several other companies are doing exciting things that may be worth watching.
Biotechnology
Moderna and Merck's personalized mRNA cancer vaccine intismeran autogene has succeeded in its first Phase 3 trial in melanoma, marking the first late-stage win for any mRNA cancer vaccine and raising profound questions about the future of oncology and the mRNA platform itself.
Policy
The FDA's new discussion paper on generative AI-enabled medical devices proposes evaluating AI systems the way physicians are evaluated. The implications for medtech, digital health, and the future of clinical AI are significant.
Biotechnology
AstraZeneca discontinues Phase 3 trial of volrustomig, its PD-1/CTLA-4 bispecific antibody in lung cancer, revealing structural challenges in displacing Keytruda and diverging fortunes in the bispecific antibody race.
Biotechnology
Epicrispr's EPI-321 produced measurable muscle growth in FSHD patients with a single dose, without altering DNA. The $90M Series C and early clinical data mark a potential inflection point for epigenetic medicine.
Biotechnology
Definium Therapeutics' Phase 3 Voyage trial shows DT120, a pharmaceutically optimized LSD formulation, achieved an 11.6-point reduction in anxiety scores—the strongest placebo-adjusted efficacy benefit ever observed in a pivotal GAD study.
Pharmaceuticals
Eli Lilly filed six lawsuits against black-market sellers of retatrutide on August 12, 2026. The legal action reveals a deeper structural tension in the obesity drug market that litigation alone cannot resolve.
Policy
Trump's executive order to reduce childhood vaccines from 17 to 11 raises critical questions about public health policy, pharmaceutical industry impacts, and the politicization of vaccine recommendations.
Biotechnology
Silence Therapeutics' Phase 2 SANRECO trial shows divesiran achieved an 88% clinical response rate in polycythemia vera patients, with quarterly dosing that could transform disease management for this rare blood disorder.
Wall Street Wire
Ten of the most followed names in biotech investing funded Entera Bio two weeks ago through its pivotal trial of EB613. Understanding the potential these investors see in Entera requires understanding the Company’s lead asset and how it could transform the way osteoporosis patients are treated.
Policy
Senators Pete Ricketts and Elissa Slotkin have introduced the Biotech Investment National Security Act (BINSA), which would subject US-China pharmaceutical deals to federal scrutiny. The bipartisan bill signals a major shift in how Washington views biotech collaboration with China.